PharmAla Forms Strategic Alliance for Enhanced US Distribution
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a dedicated biotechnology company, is excited to share its latest strategic move aimed at improving service delivery in the United States. The company has engaged a trusted third-party logistics partner, specialized in the pharmaceutical sector, to streamline its US distribution of LaNeo™ MDMA, which is critical for its clinical trials.
Addressing Shipping Challenges
Recent months have revealed an increase in uncertainties surrounding cross-border shipping between the US and Canada. This growing concern threatens to disrupt PharmAla's many clinical trial clients located in the US. Nicholas Kadysh, the CEO of PharmAla, emphasized the necessity to optimize operations amidst these challenges. As the demand for their products in the US escalates, PharmAla recognizes the importance of having a reliable logistics partner, especially with potential tariff barriers looming.
Commitment to Quality and Compliance
The agreement with this logistics partner is poised to provide a robust and GMP-compliant supply chain for LaNeo™ MDMA, catering to both existing clients and those looking to enter clinical trials in the future. This partnership not only enhances the reliability of their product distribution but also mitigates import and export risks associated with moving pharmaceutical products across borders.
Non-Exclusive Agreement and Future Prospects
It is essential to note that the agreement is non-exclusive, meaning that while this partner will handle storage and distribution for PharmAla, they will not engage in direct sales of LaNeo™ MDMA. The details surrounding the identity of the logistics partner remain confidential, per their request. This collaboration follows closely after PharmAla announced a significant exclusive distribution deal with Duchefa Farma based in the Netherlands.
About PharmAla
PharmAla Biotech Holdings Inc. is renowned for its commitment to research and development of MDXX class molecules. The company was established with a dual mission: to alleviate the backlog of clinical-grade MDMA while enabling both clinical trials and future commercial sales in chosen jurisdictions. An essential player in the sector, PharmAla is the only entity in a position to offer clinical-grade MDMA to patients outside of formal clinical trials.
Innovative Developments and Future Aspirations
The R&D department at PharmAla has made significant strides, successfully completing proof-of-concept studies for several intellectual property families, prominently featuring ALA-002 as their leading drug candidate. With a firm foundation built on regulatory compliance and fostering relationships with key industry regulators, PharmAla is aligning itself for significant advancements in the evolving landscape of psychedelics.
Contact PharmAla for More Information
For further insights or inquiries regarding ongoing projects and developments, you’re encouraged to reach out directly to Nicholas Kadysh, Chief Executive Officer of PharmAla Biotech. He is available via email at press@PharmAla.ca or by phone at 1-855-444-6362. More information about PharmAla’s initiatives and products can be found at www.PharmAla.ca.
Frequently Asked Questions
What is PharmAla Biotech Holdings Inc. known for?
PharmAla is recognized for its research and development of MDXX class molecules, particularly in the area of clinical-grade MDMA.
Who is PharmAla's logistics partner?
The name of PharmAla's logistics partner remains confidential at their request, but they specialize in pharmaceutical product distribution.
What recent agreements has PharmAla made?
In addition to the logistics agreement, PharmAla recently secured an exclusive distribution agreement with Duchefa Farma in the Netherlands.
How does the logistics partner improve PharmAla's operations?
The logistics partner enhances PharmAla's operational efficiency by ensuring GMP compliance and mitigating cross-border shipment challenges.
What is PharmAla’s lead drug candidate?
PharmAla’s lead drug candidate is ALA-002, developed through their innovative research and development efforts.
